A Matched Cohort Study of Regranex (Becaplermin) and the Risk of Cancer.

Trial Profile

A Matched Cohort Study of Regranex (Becaplermin) and the Risk of Cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Becaplermin (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions
  • Sponsors Ethicon
  • Most Recent Events

    • 15 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 20 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top